CASI
CASI
NASDAQ · Biotechnology

Casi Pharmaceuticals Inc

$0.15
+0.01 (+3.57%)
As of May 23, 2:26 AM ET ·
Financial Highlights (FY 2026)
Revenue
31.91M
Net Income
-43,899,281
Gross Margin
55.9%
Profit Margin
-137.6%
Rev Growth
-1.8%
D/E Ratio
9.93
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 55.9% 55.9% 60.0% 60.0%
Operating Margin -138.8% -125.0% 5.5% 5.7%
Profit Margin -137.6% -130.7% 4.6% 6.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 31.91M 32.51M 9.51M 9.21M
Gross Profit 17.83M 18.17M 5.70M 5.53M
Operating Income -44,304,799 -40,621,759 525.4K 529.8K
Net Income -43,899,281 -40,249,952 434.3K 561.3K
Gross Margin 55.9% 55.9% 60.0% 60.0%
Operating Margin -138.8% -125.0% 5.5% 5.7%
Profit Margin -137.6% -130.7% 4.6% 6.1%
Rev Growth -1.8% -1.8% +3.9% +7.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.13M 1.13M 2.23M 2.01M
Total Equity 113.8K 113.8K 5.80M 5.32M
D/E Ratio 9.93 9.93 0.38 0.38
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -44,285,235 -42,859,589 716.5K 618.7K
Free Cash Flow 350.1K 392.2K